BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer.
BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer.
复制标题
BRD4-IRF1 轴调节非小细胞肺癌放化疗诱导的 PD-L1 表达和免疫逃避
DOI：
10.1002/ctm2.718
复制
发表时间：
2022-01
影响因子：
10.6
通讯作者：
Wu G
中科院分区：
文献类型：
--
作者：
Wang J;Xu Y;Rao X;Zhang R;Tang J;Zhang D;Jie X;Zhu K;Wang X;Xu Y;Zhang S;Dong X;Zhang T;Yang K;Xu S;Meng R;Wu G
Chemoradiotherapy‐induced PD‐L1 upregulation leads to therapeutic resistance and treatment failure. The PD‐1/PD‐L1 blocking antibodies sensitize cancers to chemoradiotherapy by blocking extracellular PD‐1 and PD‐L1 binding without affecting the oncogenic function of intracellular PD‐L1. Reversing the chemoradiation‐induced PD‐L1 expression could provide a new strategy to achieve a greater anti‐tumour effect of chemoradiotherapy. Here, we aimed to identify candidate small molecular inhibitors that might boost the anti‐tumour immunity of chemoradiotherapy by decreasing treatment‐induced PD‐L1 expression in non‐small cell lung cancer (NSCLC). A drug array was used to recognize compounds that can suppress the cisplatin‐induced and radiation‐induced PD‐L1 expression in NSCLC via the flow cytometry‐based assay. We examined whether and how targeting bromodomain containing 4 (BRD4) inhibits chemoradiation‐induced PD‐L1 expression and evaluated the effect of BRD4 inhibition and chemoradiation combination in vivo. BRD4 inhibitors JQ1 and ARV‐771 were identified as the most promising drugs both in the cisplatin and radiation screening projects in two NSCLC cell lines. Targeting BRD4 was supposed to block chemoradiotherapy inducible PD‐L1 expression by disrupting the recruitment of BRD4‐IRF1 complex to PD‐L1 promoter. A positive correlation between BRD4 and PD‐L1 expression was observed in human NSCLC tissues. Moreover, BRD4 inhibition synergized with chemoradiotherapy and PD‐1 blockade to show a robust anti‐tumour immunity dependent on CD8+ T cell through limiting chemoradiation‐induced tumour cell surface PD‐L1 upregulation in vivo. Notably, the BRD4‐targeted combinatory treatments did not show increased toxicities. The data showed that BRD4‐targeted therapy synergized with chemoradiotherapy and anti‐PD‐1 antibody by boosting anti‐tumour immunity in NSCLC. (1) The flow cytometry‐based drug screening experiments showed that bromodomain Containing 4 (BRD4) inhibitors can simultaneously reverse the expression of PD‐L1 in NSCLC tumour cells induced by radiotherapy and cisplatin treatment. (2) Radiotherapy and chemotherapy up‐regulating PD‐L1 expression via the BRD4/IRF1 axis in NSCLC. (3) Targeting BRD4 boosted anti‐tumour immunity of chemoradiotherapy dependent on CD8+ T cells in vivo.
登录
查看更多内容
DOI：
10.1126/science.aac9935
发表时间：
2016-04-08
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Casey SC;Tong L;Li Y;Do R;Walz S;Fitzgerald KN;Gouw AM;Baylot V;Gütgemann I;Eilers M;Felsher DW
通讯作者：
Felsher DW
DOI：
10.1126/science.aaz8455
发表时间：
2020-04-24
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Gilan O;Rioja I;Knezevic K;Bell MJ;Yeung MM;Harker NR;Lam EYN;Chung CW;Bamborough P;Petretich M;Urh M;Atkinson SJ;Bassil AK;Roberts EJ;Vassiliadis D;Burr ML;Preston AGS;Wellaway C;Werner T;Gray JR;Michon AM;Gobbetti T;Kumar V;Soden PE;Haynes A;Vappiani J;Tough DF;Taylor S;Dawson SJ;Bantscheff M;Lindon M;Drewes G;Demont EH;Daniels DL;Grandi P;Prinjha RK;Dawson MA
通讯作者：
Dawson MA
影响因子：
11.2
作者：
Fukumoto, Takeshi;Fatkhutdinov, Nail;Zhang, Rugang
通讯作者：
Zhang, Rugang
联合放疗与抗PD-L1抗体协同增强非小细胞肺癌的抗肿瘤作用
影响因子：
20.4
作者：
Gong, Xiaomei;Li, Xuefei;Zhou, Caicun
通讯作者：
Zhou, Caicun
影响因子：
11.5
作者：
Lim, Su Y.;Lee, Jenny H.;Rizos, Helen
通讯作者：
Rizos, Helen